Study Suggests IL-6 Blockers Prevent MOGAD Relapses

An international study, led by Mayo Clinic researchers and published in JAMA Neurology, indicates that interleukin-6 (IL-6) receptor blockers show promise in preventing relapses for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). This rare autoimmune neurological disorder can cause vision loss and paralysis. The findings offer crucial real-world evidence to guide treatment decisions while randomized clinical trials are ongoing.